Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled phase 2 trial of ofatumumab in moderate to severe COPD
2006-003184-31Phase 2Terminated
- Sponsor
- Genmab
- Start
- May 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic obstructive pulmonary disease (COPD) comparing Ofatumumab with Placebo (2 arms). Primary endpoint: Change in bronchial biopsy inflammatory cell counts. Started May 2007; status: terminated.
02
Drugs
ofatumumab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2006-003184-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003184-31.